PHARNEXT
🏢 View company profile →54Patents
54Active
54Granted
53Portfolio score
Filing activity: Nov 28, 2008 → Mar 8, 2021 · 7 expiring within 5 years
Most-cited patents
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US8716269B2 | Combination of pilocarpin and methimazol for treating Charcot-Marietooth disease and related disorders | Human Necessities | 19 | Active |
| US8992891B2 | Therapeutic approaches for treating CMT and related disorders | Human Necessities | 18 | Active |
| US8741886B2 | Baclofen and acamprosate based therapy of neurological disorders | Human Necessities | 17 | Active |
| US9241933B2 | Compositions for treating amyotrophic lateral sclerosis | Human Necessities | 15 | Active |
| US9393241B2 | Compositions for treating CMT and related disorders | Human Necessities | 13 | Active |
| US9566275B2 | Compositions for treating CMT and related disorders | Human Necessities | 13 | Active |
| US9427436B1 | Compositions for treating CMT and related disorders | Human Necessities | 13 | Active |
| US8865769B2 | Baclofen and acamprosate based therapy of neurological disorders | Human Necessities | 13 | Active |
| US8809302B2 | Therapeutic approaches for treating alzheimer'S disease | Human Necessities | 12 | Active |
| US9248111B2 | Therapeutic approaches for treating parkinson's disease | Human Necessities | 6 | Active |
| US9144558B2 | Baclofen and acamprosate based therapy of neurological disorders | Human Necessities | 6 | Active |
| US9931326B2 | Composition comprising torasemide and baclofen for treating neurological disorders | Human Necessities | 5 | Active |
| US9636316B2 | Baclofen and acamprosate based therapy of neurological disorders | Human Necessities | 5 | Active |
| US10300015B2 | Stable oral solutions for combined API | Human Necessities | 5 | Active |
| US10004744B2 | Therapeutic approaches for treating Parkinson's disease | Human Necessities | 3 | Active |
| US9867837B2 | Compositions for treating neurological disorders | Human Necessities | 3 | Active |
| US10010515B2 | Therapeutic approaches for treating Parkinson's disease | Human Necessities | 3 | Active |
| US9820978B2 | Treatment of cerebral ischemia | Human Necessities | 3 | Active |
| US9387206B2 | Therapeutic approaches for treating Alzheimer's disease | Human Necessities | 3 | Active |
| US10045971B2 | Compositions for treating amyotrophic lateral sclerosis | Human Necessities | 3 | Active |
| US8552041B2 | Therapeutic approaches for treating alzheimer disease and related disorders through a modulation of cell stress response | Human Necessities | 3 | Active |
| US10434109B2 | Compositions for treating neurological disorders | Human Necessities | 2 | Active |
| US10342784B2 | Compositions for treating amyotrophic lateral sclerosis | Human Necessities | 2 | Active |
| US10342768B2 | Therapeutic approaches for treating Parkinson's disease | Human Necessities | 2 | Active |
| US10322101B2 | Therapeutic approaches for treating CMT and related disorders | Human Necessities | 2 | Active |
Source: USPTO / EPO open patent data. Counts and citation impact are objective bibliographic measures.